Results 61 to 70 of about 1,603 (142)

Quantitative Assessment of the BCR-ABL Transcript Using the Cepheid Xpert BCR-ABL Monitor Assay

Archives of Pathology & Laboratory Medicine, 2007
Abstract Context. —Chronic myelogenous leukemia (CML) and the assessment of the BCR-ABL transcript has become a new paradigm. Novel tyrosine kinase inhibitors as mainstream therapeutic options for the CML patient warrant routine quantification of the
Scott D, Dufresne, Dorothy R, Belloni, Norman B, Levy, Gregory J, Tsongalis   +3 more
openaire   +2 more sources

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY

The Iraqi Journal of Medical Sciences, 2016
Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi, Nidhal Abdul Mohaymen, Nabeel S. Murad   +2 more
doaj   +6 more sources

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Blood, 2008
Several RNA binding proteins (RBPs) have been implicated in the progression of chronic myelogenous leukemia (CML) from the indolent chronic phase to the aggressively fatal blast crisis. In the latter phase, expression and function of specific RBPs are aberrantly regulated at transcriptional or posttranslational levels by the constitutive kinase ...
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti Passerini C, VOLINIA, Stefano, Marcucci G, Caligiuri MA, Leone GW, Perrotti D.   +12 more
openaire   +5 more sources

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Astrid Lipplaa, Nadia Hindi, Pawel Teterycz, Robin J. Young, Ioannis Boukonavis, Josefina Cruz, Javier Martinez‐Trufero, Frank Speetjens, Wilco Peul, Robert J. P. van der Wal, Hans Gelderblom   +10 more
wiley   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl, Elaine Del Nery, Pierre Gestraud, Maral Halladjian, Elodie Girard, Adèle Soria, Elodie Anthony, Leanne De Koning, Nicolas Servant, Els Berns, Maud Kamal   +10 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Role of STAT3 in transformation and drug resistance in CML

Frontiers in Oncology, 2012
Chronic Myeloid Leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors.
Rajesh R Nair, Joel H Tolentino, Lori A Hazlehurst   +2 more
doaj   +1 more source

Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis

Neoplasia: An International Journal for Oncology Research, 2018
Suppressor of cytokine signaling 3 (SOCS3) is involved in Bcr-Abl–induced tumorigenesis. However, how SOCS3 interacts with Bcr-Abl and is regulated by Abl kinases remains largely unknown.
Riyue Feng, Xuefei Wang, Jianning Li, Ke Chen, Guijie Guo, Yuan Liao, Liping Sun, Shile Huang, Ji-Long Chen   +8 more
doaj   +1 more source

Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Mohammad Shahzaib Qadir, Shereen Farooq, Omer Jamy   +2 more
wiley   +1 more source